Street bets on Torrent Pharma's domestic business

Synergy benefits from acquisition of Unichem's products may raise earnings

The Torrent Pharma stock has risen 20 per cent since its March lows and is currently trading near its 52-week high. Street sentiment remains strong on its domestic growth, as was seen in the March quarter performance. With the pharma market growth crossing 10 per cent in May, sentiment for domestic-focused firms such as Torrent has improved further.
 
The company, which had purchased Unichem’s domestic portfolio about a year back, is likely to continue accruing benefits as it turns around this business. Having a strong-track record in turning around acquisitions, the synergy benefits is expected to start reflecting in